These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9652307)

  • 1. Inhibitory effects of lodoxamide on eosinophil activation.
    Capron M; Loiseau S; Papin JP; Robertson S; Capron A
    Int Arch Allergy Immunol; 1998 Jun; 116(2):140-6. PubMed ID: 9652307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases.
    Woerly G; Loiseau S; Loyens M; Schoch C; Capron M
    Allergy; 2003 May; 58(5):397-406. PubMed ID: 12752326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators.
    Aldebert D; Lamkhioued B; Desaint C; Gounni AS; Goldman M; Capron A; Prin L; Capron M
    Blood; 1996 Mar; 87(6):2354-60. PubMed ID: 8630398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
    Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
    Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis.
    Leonardi A; Borghesan F; Avarello A; Plebani M; Secchi AG
    Br J Ophthalmol; 1997 Jan; 81(1):23-6. PubMed ID: 9135403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis.
    Schoch C
    J Ocul Pharmacol Ther; 2003 Apr; 19(2):153-9. PubMed ID: 12804060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF alpha-induced activation of eosinophil oxidative metabolism and morphology--comparison with IL-5.
    Zeck-Kapp G; Czech W; Kapp A
    Exp Dermatol; 1994 Aug; 3(4):176-88. PubMed ID: 8000707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophil granule proteins activate human heart mast cells.
    Patella V; de Crescenzo G; Marinò I; Genovese A; Adt M; Gleich GJ; Marone G
    J Immunol; 1996 Aug; 157(3):1219-25. PubMed ID: 8757629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granular proteins of eosinophils.
    Monteseirín J; Prados M; Bonilla I; Llamas E; Delgado J; Sánchez-Monteseirín H; Chaparro A; Conde J
    Allergol Immunopathol (Madr); 1996; 24(5):219-25. PubMed ID: 8985478
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins.
    Hamann KJ; Gleich GJ; Checkel JL; Loegering DA; McCall JW; Barker RL
    J Immunol; 1990 Apr; 144(8):3166-73. PubMed ID: 2324497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein.
    Winqvist I; Olofsson T; Olsson I
    Immunology; 1984 Jan; 51(1):1-8. PubMed ID: 6317543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils.
    Kita H; Abu-Ghazaleh RI; Sur S; Gleich GJ
    J Immunol; 1995 May; 154(9):4749-58. PubMed ID: 7722326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens.
    Rosenberg HF; Domachowske JB
    J Leukoc Biol; 2001 Nov; 70(5):691-8. PubMed ID: 11698487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial purification and biological properties of an eosinophil-activating factor.
    Thorne KJ; Richardson BA; Veith MC; Tai PC; Spry CJ; Butterworth AE
    Eur J Immunol; 1985 Nov; 15(11):1083-91. PubMed ID: 2998804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of mediators released by eosinophils.
    Capron M; Tomassini M; Torpier G; Kusnierz JP; MacDonald S; Capron A
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):54-8. PubMed ID: 2523359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer.
    Trulson A; Nilsson S; Venge P
    Br J Haematol; 1997 Aug; 98(2):312-4. PubMed ID: 9266926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of eosinophils in bronchial asthma].
    Pałczyński C; Górski P
    Pol Arch Med Wewn; 1988 Jun; 79(6):332-7. PubMed ID: 3078201
    [No Abstract]   [Full Text] [Related]  

  • 18. The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF.
    Kapp A; Zeck-Kapp G; Czech W; Schöpf E
    J Invest Dermatol; 1994 Jun; 102(6):906-14. PubMed ID: 7516398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Eosinophil-induced lung injury].
    Iwamoto I
    Kokyu To Junkan; 1991 Jun; 39(6):514-21. PubMed ID: 1871435
    [No Abstract]   [Full Text] [Related]  

  • 20. Pitfalls in the quantitative estimation of the secretion of granule proteins by eosinophils.
    Bach MK; Brashler JR; Sanders ME; Bienkowski MJ
    J Immunol Methods; 1991 Sep; 142(2):243-50. PubMed ID: 1919027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.